RSI Overbought Stocks
TVTX is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
TRAVERE THERAPEUTICS INC (TVTX) Stock Price & Overview
NASDAQ:TVTX • US89422G1076
Current stock price
44.12 USD
+2 (+4.75%)
At close:
43.9484 USD
-0.17 (-0.39%)
After Hours:
The current stock price of TVTX is 44.12 USD. Today TVTX is up by 4.75%. In the past month the price increased by 44.94%. In the past year, price increased by 108.6%.
TVTX Key Statistics
52-Week Range13.88 - 44.7
Current TVTX stock price positioned within its 52-week range.
1-Month Range28.29 - 44.7
Current TVTX stock price positioned within its 1-month range.
- Market Cap
- 4.075B
- P/E
- N/A
- Fwd P/E
- 255.95
- EPS (TTM)
- -0.30
- Dividend Yield
- N/A
TVTX Stock Performance
Today
+4.75%
1 Week
+8.94%
1 Month
+44.94%
3 Months
+41.91%
Longer-term
6 Months +25.48%
1 Year +108.60%
2 Years +494.61%
3 Years +146.62%
5 Years +190.84%
10 Years N/A
TVTX Stock Chart
TVTX Stock Screens
TVTX currently appears in the following ChartMill screener lists.
TVTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TVTX. When comparing the yearly performance of all stocks, TVTX is one of the better performing stocks in the market, outperforming 93.74% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TVTX. TVTX has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TVTX Earnings
On February 19, 2026 TVTX reported an EPS of 0.03 and a revenue of 129.69M. The company beat EPS expectations (124.93% surprise) and missed revenue expectations (-10.61% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported$0.03
Revenue Reported129.689M
EPS Surprise 124.93%
Revenue Surprise -10.61%
TVTX Forecast & Estimates
21 analysts have analysed TVTX and the average price target is 50.45 USD. This implies a price increase of 14.35% is expected in the next year compared to the current price of 44.12.
For the next year, analysts expect an EPS growth of 157.46% and a revenue growth 38.47% for TVTX
Analysts
Analysts84.76
Price Target50.45 (14.35%)
EPS Next Y157.46%
Revenue Next Year38.47%
TVTX Index Membership
TVTX is currently included in the following stock indexes tracked on ChartMill.
TVTX Financial Highlights
Over the last trailing twelve months TVTX reported a non-GAAP Earnings per Share(EPS) of -0.3. The EPS increased by 92.68% compared to the year before.
Income Statements
Revenue(TTM)490.73M
Net Income(TTM)-25.55M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.22% | ||
| ROE | -22.25% | ||
| Debt/Equity | 2.71 |
Chartmill High Growth Momentum
EPS Q2Q%104.11%
Sales Q2Q%73.41%
EPS 1Y (TTM)92.68%
Revenue 1Y (TTM)110.46%
TVTX Ownership
Ownership
Inst Owners110.99%
Shares92.37M
Float86.81M
Ins Owners0.88%
Short Float %14.66%
Short Ratio6.56
TVTX Industry Overview
TVTX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
TVTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TVTX
Company Profile
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 497 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Company Info
IPO: 2003-07-23
TRAVERE THERAPEUTICS INC
3611 Valley Centre Dr, Suite 300
San Diego CALIFORNIA 92130 US
CEO: Eric M. Dube
Employees: 497
Phone: 18889697879
TRAVERE THERAPEUTICS INC / TVTX FAQ
What does TRAVERE THERAPEUTICS INC do?
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 497 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
What is the current price of TVTX stock?
The current stock price of TVTX is 44.12 USD. The price increased by 4.75% in the last trading session.
What is the dividend status of TRAVERE THERAPEUTICS INC?
TVTX does not pay a dividend.
How is the ChartMill rating for TRAVERE THERAPEUTICS INC?
TVTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of TRAVERE THERAPEUTICS INC (TVTX)?
TRAVERE THERAPEUTICS INC (TVTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.3).
What is the ownership structure of TRAVERE THERAPEUTICS INC (TVTX)?
You can find the ownership structure of TRAVERE THERAPEUTICS INC (TVTX) on the Ownership tab.